The MDMA Therapy Training Program has launched a series of trainings to prepare therapy providers to become eligible to work on an MDMA-assisted psychotherapy for PTSD protocol. From June 23-29, 2019, Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D., led a six-and-a-half-day training retreat in Northern California focused on MDMA-assisted psychotherapy for PTSD. This retreat was organized by the CIIS’ Center for Psychedelic Therapies and Research (CPTR) with support from the MDMA Therapy Training Program. More than 90 practitioners travelled from across the U.S. and internationally to receive training.
Annie and Michael Mithoefer will be leading an upcoming training retreat October 1-8, 2019 in Asheville, North Carolina. Eligible therapy providers interested in this event can submit the MDMA Therapy Training Application and respond ”yes” to the question about interest in this event. For those who have already completed applications, you will be automatically considered for this fall event and do not need to re-apply. Future training retreats will be announced through the training newsletter as they are scheduled.
The MDMA Therapy Training for Communities of Color event will take place August 10-17, 2019, in Louisville, Kentucky, led by Marcela Ot’alora M.A., L.P.C., and Monnica Williams, Ph.D., A.B.P.P., with support from additional trainers. Registration is now full for the 6-day training retreat taking place August 11-17, 2019. The 1.5-day Psychedelic Medicine and Cultural Trauma Community Workshop will take place August 10-11 and is open to the public with tickets available online. Scholarships and tiered tuition rates, for both therapy providers and affiliated community organizers who work with communities of color, are currently available for this event through generous funding from the Open Society Foundation (OSF), Libra Foundation, Riverstyx Foundation, Psychedelic Science Funders Collaborative (PSFC), and Dr. Bronner’s. Applicants who applied for this event will receive more information about the scholarship process. Additional scholarship programs are under development. For questions about this event, please email email@example.com.
In January 2019, MAPS Public Benefit Corporation (MAPS PBC) submitted an MDMA-assisted psychotherapy for PTSD protocol to the U.S. Food and Drug Administration (FDA) as part of an application to participate in the FDA Expanded Access (EA) program. We’ve received and responded to several rounds of comments from FDA regarding our protocol submission for Expanded Access (EA), and we will hear from FDA this month. The Expanded Access program’s purpose is to grant access to potentially beneficial investigational treatments for individuals or populations facing a serious or immediately life-threatening condition for which there is no satisfactory treatment currently available. If approved, Expanded Access would allow additional qualified sites to provide MDMA-assisted psychotherapy for participants with treatment-resistant PTSD under a MAPS protocol.
Sites in the U.S. and U.S. territories interested in being considered to participate in an MDMA/PTSD protocol may now apply with MAPS PBC to assess eligibility and obtain the prerequisite training to administer MDMA-assisted psychotherapy. The basic requirements of a qualified site are 1) treatment facility conducive to MDMA-assisted psychotherapy, 2) therapy team, qualified and able to complete MDMA Therapy Training Program, and 3) prescribing physician who can obtain a DEA Schedule I license for MDMA.
Site and practitioner application procedures are posted on our website. Each site must submit one site questionnaire. Only applicants affiliated with a qualifying site can be considered for training at this time. MAPS PBC will review applications on an ongoing basis, as they are received.
Sign up and stay tuned to the Training Program Newsletter to receive updates on upcoming trainings. • Learn More